SME Times is powered by   
Search News
Just in:   • Indian equity indices end slightly lower ahead of RBI's MPC outcome  • J&K’s Kishtwar selected as aspirational agricultural district under PMDDKY  • Indian stock market opens higher as RBI MPC begins  • Mumbai-Ahmedabad bullet train to be fully operational by 2029: Ashwini Vaishnaw  • Nifty, Sensex see sharp decline this week amid H-1B, pharma tariff concerns 
Last updated: 27 Sep, 2014  

SIRO Clinpharm Deploys Oracle Health Sciences InForm

PR Newswire | 30 Nov, 2012
SIRO Clinpharm Deploys Oracle Health Sciences InForm to Enhance Global EDC Studies

MUMBAI, India: SIRO Clinpharm, a leading full service Clinical Research Organization, announced the deployment of one of the biggest IT advancement projects in the region - Oracle Health Sciences InForm - an integrated life sciences solution with all the tools required to efficiently conduct and manage EDC-based clinical trials.

The application of Oracle Health Sciences InForm enables SIRO to automate and streamline solutions for the global biopharma and medical devices companies in their clinical development process across therapeutic areas and phases. With a breadth of services encompassing clinical operations, clinical data management, medical writing, biostatistics and statistical programming, pharmacovigilance and clinical trial supplies management, this comes as a huge step toward adopting global trial processes, as EDC systems are widely used across Western Europe and the United States.

"Our IT capabilities in the region are second to none. By deploying Oracle Health Sciences InForm, we have upgraded our technology platforms to global standards.   Combined with our expertise in clinical development, we can now offer our clients a very effective and seamless user experience," said Khushru Patel, Global Head, Information Technology.  "The software's flexibility, scalability and real-time access to trial data streamline and accelerate large and complex international trials."

"We help our clients take advantage of technology developments to tackle dynamic regulatory environments, escalating disease complications and fierce competition to get products to the market," said Gopakumar Menon, CEO.

About SIRO Clinpharm:

SIRO Clinpharm, winner of Frost & Sullivan 'Clinical Research Organization of the year 2012' India Healthcare Award, is a drug development solutions provider to the global healthcare industry.

Our subject expertise gives us an edge in clinical data management, medical writing, biostatistics, clinical trial management and clinical trial supplies. Our therapeutic experience includes but is not limited to oncology, diabetes, cardiology, infectious diseases & respiratory disorders. We offer flexible business models across service verticals based on client needs.

Our geographic spread and global expertise backed by local operations deliver excellence in our customized solutions.

Visit us at http://www.siroclinpharm.com.

About Oracle

Oracle engineers hardware and software to work together in the cloud and in your data center.  For more information about Oracle (NASDAQ:ORCL), visit http://www.oracle.com.

Trademarks

Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Media Contact:
Ruchi Sanganeria
Corporate Marketing
E: ruchi.sanganeria@siroclinpharm.com
P: +91(0)22-2584-8000

SOURCE SIRO Clinpharm

 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
₹84.00
₹82.25
UK Pound
₹104.65
₹108.10
Euro
₹92.50
₹89.35
Japanese Yen ₹56.10 ₹54.40
As on 25 Jul, 2025
  Daily Poll
Who do you think will benefit more from the India - UK FTA in the long run?
 Indian businesses & consumers.
 UK businesses & consumers.
 Both will gain equally.
 The impact will be negligible for both.
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter